(Total Views: 424)
Posted On: 01/18/2019 9:31:35 PM
Post# of 15624
Potentially, I think the cannabinoid-enriched sublingual soluble tablet is the sleeper that will start generating revenue before anything else.
https://www.prnewswire.com/news-releases/owc-...68089.html
The above December, 2018 press release stated:
What I didn’t realize is that the pharmaceutical they were referring to is the nabixomols by GW Pharmaceuticals, sold under the trade name Sativex.
If the results showed that our Company’s soluble tablet was more effective, I think it would be the needed catalyst to turn the sp in a new direction, and change the mood of its long suffering investors forever!
https://www.prnewswire.com/news-releases/owc-...68089.html
The above December, 2018 press release stated:
Quote:
In addition, OWCP has applied for an amendment to its study protocols to enable the comparison of its tablet with a known cannabis-based pharmaceutical, which is registered for treatment of spasticity in Multiple Sclerosis patients.
What I didn’t realize is that the pharmaceutical they were referring to is the nabixomols by GW Pharmaceuticals, sold under the trade name Sativex.
If the results showed that our Company’s soluble tablet was more effective, I think it would be the needed catalyst to turn the sp in a new direction, and change the mood of its long suffering investors forever!
(0)
(0)
